JZB 30
Alternative Names: JZB-30Latest Information Update: 10 Jan 2023
At a glance
- Originator Shanghai Jingze Biotechnology
- Class Infertility therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preregistration Female infertility
Most Recent Events
- 10 Jan 2023 Preregistration for Female infertility in China (Parenteral) prior to January 2023
- 13 Sep 2022 JZB 30 is available for licensing as of 23 Aug 2022. https://jingzepharma.com/en/coop.html
- 01 Jan 2021 Shanghai Jingze Biotechnology completes enrolment in phase III trial in Female infertility in China (Parenteral) (Shanghai Jingze Biotechnology website, August 2022)